anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Perianal fistulizing Crohn's disease (CD) is a severe gastrointestinal disorder causing extensive mucosal damage with limited treatment options. Severe manifestations of the disease appear at higher rates in non-Europeans but the genetic and cellular mechanisms driving the disease phenotypes remain poorly understood. Herein, we tested whether pathologic determinants in the epithelial stem cell compartment could be detected at the transcript level in rectal organoids derived from a diverse patient population. Rectal organoid and mucosal cells from endoscopic biopsies of each patient having perianal fistulizing CD or no disease controls were prepared for and sequenced at the single cell level. After cell type annotations based on expressed marker genes, samples were analyzed by principal components, for differential transcript expression, cell type proportions, and pathway enrichment. After QC, we produced 77,044 rectal organoid cells (n = 13 patients; 8 CD, 5 controls) with high quality sequences that identified 10 distinct epithelial subtypes, that we compared to 141,367 mucosal epithelial cells (n = 29 patients; 18 CD, 11 controls). Consistent with mucosal epithelial cells, rectal organoids prominently displayed disease signatures represented by the stem and transit amplifying regions of the rectal crypt, including alterations in transcriptional signatures of metabolic, epigenetic, and proliferating pathways. Organoids also retained their gender- and ancestral-specific gene expression signatures. However, they lacked many of the inflammatory signatures observed in epithelial cells from diseased mucosa. Perianal CD patient derived rectal organoids reflect gene expression signatures related to disease, gender, and ancestry, suggesting they harbor inherent properties amenable to further patient-specific, disease-related experimentation.
ADHD affects from 3 to 5% of children, persists into adolescence 40 to 70% of these children and continues into adulthood in at least 50% of affected adolescents. Pharmacotherapy for ADHD in adults has paralleled that used for children, with generally positive results (Spencer, 1998). Never-the-less, it is not clear that the dimensions of medication response in adults are the same as in children. The extent to which the symptoms change with age remains open to question. This trial is created to include a variety of outcome measures which will enhance the number of symptoms assessed.

Methylphenidate was the first medication shown to be effective in treatment for adults with ADHD and continues to be widely used. Several studies have demonstrated the usefulness of methylphenidate in adult ADHD (Wender et al, 1985, Spencer et al, 1995). These studies have not shown any unexpected drawbacks to treatment with methylphenidate. The extended release formulations represent an improvement over the immediate release versions for many patients.

This is a double-blind, placebo-controlled, randomized, crossover trial comparing OROS methylphenidate with placebo. The double-blind trial will be preceded by an enrollment period consisting of a screening visit followed by a baseline visit. Patients who continue to meet admission criteria at baseline will be randomized into the first of two 4-week treatment periods. We will attempt to reach the highest tolerated dose size within 2 weeks and then observe the response over the last two weeks of each crossover phase. The double-blind period will be followed by a 180 day open-treatment, flexible-dose phase designed to assess long-term effects.
This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. "Arm" 2 corresponds to Wave 2.
Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to suppositories exhibiting vasodilating and spasmolytic effects. Suppositories have dibazol - 0.002 g per a single suppository (mass is 1.15-1.40 g). Base is solid candy fat of type A on the basis of plasticized hydrogenated fat or vitepsol - a mixture of triglycerides, diglycerides and monoglycerides of C 12 -C 18 -fatty acids. The use of suppositories excludes irritating effect on rectum intestine mucosa in children. Suppositories can be recommended for children with nausea and vomiting especially. Suppositories do not show adverse responses in baby organism. EFFECT: enhanced effectiveness of treatment. 1 tbl
Background: The transition to spontaneous breathing puts patients who are undergoing ventilator withdrawal at high risk for developing respiratory distress. A patient-centered algorithmic approach could standardize this process and meet unique patient needs because a single approach (weaning vs. one-step extubation) does not capture the needs of a heterogenous population undergoing this palliative procedure. Objectives: (1) Demonstrate that the algorithmic approach can be effective to ensure greater patient respiratory comfort compared to usual care; (2) determine differences in opioid or benzodiazepine use; (3) predict factors associated with duration of survival. Design/Settings/Measures: A stepped-wedge cluster randomized design at five sites was used. Sites crossed over to the algorithm in random order after usual care data were obtained. Patient comfort was measured with the Respiratory Distress Observation Scale© (RDOS) at baseline, at ventilator off, and every 15-minutes for an hour. Parenteral morphine and lorazepam equivalents from the onset of the process until patient death were calculated. Results: Usual care data n = 120, algorithm data n = 48. Gender and race were evenly distributed. All patients in the usual care arm underwent a one-step ventilator cessation; 58% of patients in the algorithm arm were weaned over an average of 18 ± 27 minutes as prescribed in the algorithm. Patients had significantly less respiratory distress in the intervention arm (F = 10.41, p = 0.0013, effective size [es] = 0.49). More opioids (t = -2.30, p = 0.023) and benzodiazepines (t = -2.08, p = 0.040) were given in the control arm. Conclusions: The algorithm was effective in ensuring patient respiratory comfort. Surprisingly, more medication was given in the usual care arm; however, less may be needed when distress is objectively measured (RDOS), and treatment is initiated as soon as distress develops as in the algorithm. Clinical Trial Registration number: NCT03121391.
The invention provides a fusion protein for preventing pseudomonas aeruginosa infection, which comprises a first peptide segment, a second peptide segment and a third peptide segment which are linearly connected and combined, wherein the amino acid sequence of the first peptide segment is SEQ ID NO. 94, the amino acid sequence of the second peptide segment is SEQ ID NO. 95, and the amino acid sequence of the third peptide segment is a third peptide segment of SEQ ID NO. 96. The invention also provides a recombinant gene for coding the fusion protein and application of the fusion protein in preventing pseudomonas aeruginosa infection. The fusion protein can effectively prevent various serotype pseudomonas aeruginosa infections.
Group A consisted of thirty postnatal women. They were treated by progressive muscle relaxation exercises three times per week for 4 weeks.
Electronic sports (Esports) has become a branch that started to gain popularity in the gaming community in the early 2000s and that more and more individuals are interested in. Esports players are often called sedentary athletes because gaming requires prolonged sedentary activity. Although studies have examined the physical activity levels of Esports players with questionnaires, they emphasize that the results may be more variable because they do not control for potential confounding factors such as gender, age, game type, and performance level. Among the questionnaires used in the studies, there was no study evaluating the player-specific physical activity level. Therefore, the aim of this study is to validate the Occupational Sitting and Physical Activity Questionnaire in individuals playing Esports. Individuals aged 12-24, who play computer games 3-4 times a week for 2-4 hours professionally or 7-14 hours a week as an amateur, and have the ability to read and understand Turkish will be included in the study. Individuals with severe physical limitations that prevent physical activity and individuals with cognitive impairment will be excluded from the study. Correlation of the scale with Visual Analogue Scale (VAS), International Physical Activity Questionnaire-Short Form for construct validity, Young Internet Addiction Test-Short Form (YİBT-SF) and Buss-Perry Aggression Scale will be tested, respectively. In order to determine the test-retest reliability of the Turkish version of the scale, individuals will be asked to fill in the scale again 7-14 days after they first filled out the scale.
A self-contained water system that provides single point water delivery is presented. The self-contained water system purifies incoming water and restructures the purified water to deliver pure, alkaline, ionized, mineral-rich water. A first stage purification of water may be performed via pre-filtering and reverse osmosis stages that sequentially remove larger and smaller particles in the water prior to storing first stage purified water into a holding tank. A second stage purification of water is performed via a closed loop purification system that sanitizes water in the holding tank so as to kill microorganisms in the water. Restructuring of the purified water in the holding tank is performed via a water conditioner stage that remineralizes the water prior to providing for end use. Water in the holding tank can be oxygenized via a vortexing device that operates on the water in the holding tank in a closed loop fashion.
The recommended dosing schedule for Striant® is the application of one buccal system (30 mg) to the gum region twice daily; morning and evening (about 12 hours apart). Striant® should be placed in a comfortable position just above the incisor tooth (on either side of the mouth). With each application, Striant® should be rotated to alternate sides of the mouth. 

Upon opening the packet, the rounded side surface of the buccal system should be placed against the gum and held firmly in place with a finger over the lip and against the product for 30 seconds to ensure adhesion. Striant® is designed to stay in position until removed. If the buccal system fails to properly adhere to the gum or should fall off during the 12-hour dosing interval, the old buccal system should be removed and a new one applied. If the buccal system falls out of position within 4 hours prior to the next dose, a new buccal system should be applied and it may remain in place until the time of next regularly scheduled dosing. 

Patients should take care to avoid dislodging the buccal system. Patients should check to see if Striant® is in place following toothbrushing, use of mouthwash and consumption of food or alcoholic/non-alcoholic beverages. Striant® should not be chewed or swallowed. To remove Striant®, gently slide it downwards from the gum towards the tooth to avoid scratching the gum.
PURPOSE:To attain the simultaneous comparison of plural arrangements in a short counting time by repeating the parallel arrangement processing of a reference arrangement data group and a new object arrangement data and increasing successively the number of the reference arrangement data group. CONSTITUTION:Among nucleic acid arrangement data or amino acid arrangement data 15(A1-AN), for example, the A1 is made into an initial reference data group B<1> and the parallel arrangement processing between respective arrangement elements is executed between it and a data A2 in a parallel arrangement processing part 13. The modified reference arrangement data group B<1> and a modified object arrangement data A'2 obtained are updated into a new reference arrangement data group B<2> by a reference arrangement data group updating part 14. Next, in the parallel arrangement processing part 13, the new object arrangement data is inputted and the parallel arrangement processing is executed between it and the updated reference arrangement data group. The obtained respective modified data group and data are updated into the new reference arrangement data group again by the updating part 14. Thus, each time one new object arrangement data An is added and the parallel arrangement processing is executed, the number of reference arrangement data group B<n-1> is increased one by one and an updating processing is executed.
FIELD: medicine; traumatology. SUBSTANCE: acupuncture points are exposed to ultraviolet rays in 1-2 days. Acupuncture points are massaged by brake method on days free of physioprocedure. Then hand is placed in maximum possible unbent position and fixed in this position. Then hen's eff albumen is applied on hand, and phosphor-calcium exchange is normalized. This procedure facilitates formation of vitamin Д.. EFFECT: simple design. 2 ex, 2 tbl
New vectors (I) have (a) a size that is smaller than that of the target cells to which they are intended to deliver an active agent, and (b) a surface charge permitting electrical attraction at a given instant with the target cells, which have a surface electrical potential whose intensity or sign varies with time. (I) are nanocapsules, or phospholipid liposomes with a size of 20-200nm. They contain a neurotropic or musculotripic agent in an amt. of 10-6 -20 wt.%. The active agent may be a membrane stabiliser or Ca, Na, K or Cl channel regulator, e.g. an alkaloid, amiodarone, verapamil or procaine. USE/ADVANTAGE - (I) may be used to modify the electrical activity of cells or syncytia. They can deliver a musculotropic or neurotropic agent to muscle or nerve fibres when in a given phase of contraction or axonic activity.
The invention discloses antihypertensive peptides prepared by ultrasonic-assisted flour weevil larva proteolysis and a preparation method thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the antihypertensive peptides is serine-methionine (Ser-Met) with the molecular weight being 236Da, or tyrosine-alanine-asparaginate (Tyr-Ala-Asn) with the molecular mass being 366Da. The invention also discloses a method for preparing the antihypertensive peptides by ultrasonic pretreatment of degreasing flour weevil larva and protease. Small molecular peptides which are high in purity, definite in structure, good in blood pressure reducing effect and can be easily absorbed are obtained. The source of materials is easily available and the cost is low. The additional value of the flour weevil can be effectively improved through the technical transformation.
Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
The invention relates to a pectin-5-fluorouracil colon cancer two-targeting prodrug and the preparation method thereof, and mainly synthesizes a two-targeting prodrug for colon cancer by utilizing an anti-cancer drug, 5-fluorouracil (5-FU), and pectin. The two-targeting prodrug for colon cancer is used for treating colon cancer and is characterized in that the 6-digit carboxyl is utilized to be combined with 5-FU directly or through different bridging groups to synthesize a series of two-targeting prodrugs for colon cancer. The prodrug first targets 5-FU to the colon by utilizing pectin to realize colon positioned release, and then 5-FU-galactose is identified through high expression of colon cancer galactin-3, and then 5-Fu is targeted to the colon cancer cells to realize two-targeting of colon cancer to treat colon cancer. The prodrug improves the selectivity of 5-FU greatly, enhances the curative effect and reduces adverse reactions. In addition, the hydrolysis fragments of pectin play a role in resisting tumor metastasis and can have a synergic action with 5-FU. The pectin-5-fluorouracil two-targeting prodrug for colon cancer focuses on the drug design ideas of drug delivery, targeting and coordination; therefore, the prodrug achieves the goal of high selectivity, high efficiency and low toxicity.
Pelvic floor symptoms may occur in women with low back pain due to dysfunction of the spinal stabilization muscles. Low back pain is the most common musculoskeletal problem experienced by the mothers of children with cerebral palsy (CP). Therefore, our aim in this study was to examine pelvic floor symptoms and symptom-related quality of life in the mothers of children with CP. The study included 48 mothers of children with CP (n = 23) or without neurodevelopmental problems (n = 25). The mothers' pelvic floor symptoms and symptom-related quality of life were evaluated with the Pelvic Floor Distress Inventory-20 (PFDI-20) and the Pelvic Floor Impact Questionnaire-7 (PFIQ-7). PFDI-20 and PFIQ-7 scores did not differ between the two groups of mothers (p > .05). Additionally, moderately significant positive correlations were found between the age of the child with CP and duration of carrying and the PFDI-20 (r = 0.419, p = .047) and PFIQ-7 (r = 0.427, p = .042) scores. Pelvic floor symptoms and symptom-related quality of life in the mothers of children with CP were similar to those in the mothers of children without neurodevelopmental problems. As the age of the child with CP and duration of carrying increase, the urinary symptoms and urinary and colorectoanal symptoms-related quality of life in their mothers may worsen.
BACKGROUND: Sexually transmitted infection is a common public health issue of youths and is characteristically transmitted through sexual intercourse. Even though early treatment for sexually transmitted infection is very important to reduce further complications and economic burden, studies to identify the proportion and the possible factor of early treatment seeking is rare in Ethiopia.
OBJECTIVE: To assess the proportion of early treatment seeking for sexually transmitted infections and associated factors among patients attending youth friendly service in Bahir Dar city health centers, northwest, Ethiopia 2023.
METHOD: Institutional based Cross-sectional study was used among 407 participants from April 25 to May 24 /2023. A systematic random sampling technique was used to select the participants. An interview-administered questionnaire was used for data collection, whereas Epi-data version 4.6.0.2 and the statistical package for statistical science version 23 were used for data entry and analysis respectively. A frequency table and bar chart were used for descriptive analysis. Multiple binary logistic regression was employed to identify the factors at p-value of <0.05. The necessary assumption of the model was also checked by the Hosmer and Lemishow test.
RESULTS: The response rate of this study was 391 (96.1%) and the proportion of early treatment for sexually transmitted infection was 108 (27.6%, 95%CI; 23-32). Good knowledge about sexually transmitted infection (AOR=1.98, 95CI%; 1.13-3.47) know about their HIV status (AOR=1.95, 95%CI; 1.13-3.36), perceive severity of sexually transmitted infection (AOR=11.23, 95%CI; 6.15-20.45), and not fear the stigma about being infected with sexually transmitted infection (AOR=2.29, 95%CI; 1.32-3.96) were the significantly associated factors for early treatment of sexually transmitted infection. CONCLUSION AND RECOMMENDATION: The proportion of early treatment for sexually transmitted infection in Bahir Dar city was low. Knowledge about STIs, testing/ knowing HIV status, perception of the severity about sexually transmitted infection, and fear of stigma about sexually transmitted infection were the statistically significant factors for early treatment of sexually transmitted infection. So the government better give attention to health education and other health promotion activities to increase the knowledge of youths about sexually transmitted infection and to change their perception of sexually transmitted infection.
The present disclosure generally relates to a method for controlling a medical device. The method may comprise tracking movement of a foot with a hands-free device and processing movement of the foot to move a cursor, wherein the cursor is disposed on a display screen of the medical device. The method may further comprise receiving a selection of at least one icon with the cursor through the hands-free device. A system for controlling a medical device may comprise a console and a display screen coupled to the console and may be configured to display a cursor. The system may further comprise a hands-free device. The hands-free device may be communicatively coupled to the console and may be operable to track movement within a tracking area and generate an output. The system may further comprise a medical device connected to the console and a processor configured to execute instructions.
Participants will receive adalimumab 160 milligrams (mg) SC at Week 0, placebo SC at Week 1, followed by adalimumab 80 mg SC and placebo SC at Weeks 2 and 3. Participants will then receive adalimumab 40 mg SC and placebo SC at Week 4 and every week thereafter through Week 31.
Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.